Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy

被引：0
|
作者：
Sheng Li
Liangjun Zhu
Li Yao
Lei Xia
Liangxi Pan
机构：
[1] Jiangsu Tumor Hospital,Oncology
[2] First Hospital Affiliated to Suzhou University,Department of Hematology
[3] Jiangsu Tumor Hospital,Department of Pathology
来源：
BMC Gastroenterology | / 14卷
关键词：
Colorectal cancer; ERCC1; TS; Real-time PCR; Adjuvant chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Liu, Yong-Ping
    Ling, Yang
    Qi, Qiu-Feng
    Zhang, Ya-Ping
    Zhang, Chang-Song
    Zhu, Chang-Tai
    Wang, Mei-Hua
    Pan, Yao-Dong
    ONCOLOGY LETTERS, 2013, 5 (03) : 935 - 942
  • [32] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [33] The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
    J E M Crozier
    R F McKee
    C S McArdle
    W J Angerson
    J H Anderson
    P G Horgan
    D C McMillan
    British Journal of Cancer, 2006, 94 : 1833 - 1836
  • [34] Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy
    Zhang, Lijian
    Yao, Ruyong
    Fang, Shibao
    Wang, Xiuwen
    Li, Xin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18375 - 18382
  • [35] Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: ACCElox registry.
    Ji, J.
    Park, Y. S.
    Liu, M.
    Raafat, J.
    Szpak, W.
    Bouzid, K.
    Cornelio, G. H.
    Brenner, B.
    Ghosn, M.
    Zalcberg, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
    Crozier, J. E. M.
    McKee, R. F.
    McArdle, C. S.
    Angerson, W. J.
    Anderson, J. H.
    Horgan, P. G.
    McMillan, D. C.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1833 - 1836
  • [37] ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt
    Kassem, Amira B.
    Salem, Salem Eid
    Abdelrahim, Mohamed E.
    Said, Amira S. A.
    Salahuddin, Ahmad
    Hussein, Marwa Mahmoud
    Bahnassy, Abeer A.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (01) : 78 - 85
  • [38] Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment
    Kornmann, M.
    Formentini, A.
    Ette, C.
    Henne-Bruns, D.
    Kron, M.
    Sander, S.
    Baumann, W.
    Kreuser, E. -D.
    Staib, L.
    Link, K. H.
    EJSO, 2008, 34 (12): : 1316 - 1321
  • [39] Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry.
    Park, Young Suk
    Ji, Jiafu
    Zalcberg, John Raymond
    Elserafy, Mostafa M.
    Buzaid, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Polymorphisms in EGFR, GSTP1, XPD, DPD, ERCC1, and UTG1A1 of colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan chemotherapy
    Chao, Chia-Ting
    Wu, Yi-Lin
    Hsu, Tai-Feng
    Wang, Jaw-Yuan
    Chang, Long-Sen
    Lin, Shiu-Ru
    BIOMARKERS AND GENOMIC MEDICINE, 2014, 6 (04) : 183 - 185
12345